Zacks Investment Research
05 Jun 2026, 22:46 UTC · 3h ago
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Top 1 mover · tap to explore
Zacks Investment Research
05 Jun 2026, 22:46 UTC · 3h ago
Top 1 mover · tap to explore
Story key points
4 claims · impact-rated
Analysts expect Bristol Myers Squibb to report year-over-year earnings growth of 10.27% ($1.61 per share) in its upcoming release. — Double-digit EPS growth is a positive fundamental catalyst that typically supports stock price appreciation.
+0.30Consensus estimates project a 4.89% year-over-year decline in revenue for the upcoming quarter to $11.67 billion. — Revenue contraction suggests a shrinking top line or pricing pressure, which may offset earnings growth.
-0.20Bristol Myers Squibb is currently trading at a Forward P/E of 8.95, a significant discount compared to the industry average of 20.92. — A deep valuation discount relative to peers may attract value investors, though it may also reflect underlying structural risks.
+0.20Continue reading
6 related stories
The Zacks Consensus EPS estimate for Bristol Myers Squibb has shifted 0.38% upward over the past month. — Slightly positive analyst sentiment usually correlates with short-term price stability or modest gains.
+0.10Ticker attribution
Model heads
The stock outperformed the S&P 500 in the latest session and analysts expect year-over-year earnings growth.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
0 dimensions · 9 clusters
No impact vector found for this article yet.
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Zacks Investment Research
3h ago
